Want to see HK:3613 full AI Analyst Report?
3613 Stock Chart & Stats
HK$6.68
HK$0.07(1.05%)
At close: 4:00 PM EDT
HK$6.68
HK$0.07(1.05%)
Day’s Range― - ―
52-Week RangeHK$6.21 - HK$9.72
Previous CloseN/A
Volume566.00K
Average Volume (3M)1.10M
Market Cap
HK$5.78B
Enterprise ValueHK$5.11K
Total Cash (Recent Filing)HK$2.28B
Total Debt (Recent Filing)HK$126.54M
Price to Earnings (P/E)14.6
Beta0.70
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.36%
Share Statistics
EPS (TTM)0.47
Shares Outstanding837,100,000
10 Day Avg. Volume975,850
30 Day Avg. Volume1,095,238
Financial Highlights & Ratios
PEG Ratio-0.83
Price to Book (P/B)1.69
Price to Sales (P/S)4.68
P/FCF Ratio8.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.50Price Target Upside57.19% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.6
Revenue Forecast (FY)HK$1.67B
Bulls Say, Bears Say
Bulls Say
Profitability & MarginsConsistently high gross and operating margins indicate durable unit economics and pricing power in the core TCM business. Sustained margins underpin long-term cash generation, fund R&D/marketing, and provide resilience to demand cycles, supporting durable profitability over 2–6 months and beyond.
Conservative Balance SheetVery low leverage and a growing equity base provide strong financial flexibility to invest, pay dividends, or absorb shocks without refinancing strain. This conservative structure supports strategic options and capital allocation discipline over the medium term.
Strong 2025 Cash GenerationA sharp rebound in operating and free cash flow in 2025 strengthens liquidity for capex, store/network investment, and dividends. Improved cash conversion in the latest year signals capacity to self-fund strategic initiatives, enhancing operational durability.
Bears Say
Weakening Revenue GrowthAn 11.4% revenue decline in 2025 and lower earnings versus prior peaks indicate demand or mix pressure and slower top-line momentum. Sustained revenue weakness can compress future margin leverage, constrain reinvestment, and limit long-term organic growth prospects.
Uneven Cash ConversionVolatile cash conversion driven by working-capital swings raises operational and liquidity risk despite accounting profits. Inconsistent cash flow complicates planning for dividends, capex, and M&A, lowering predictability of free-cash-flow generation across cycles.
Declining Return On EquityA meaningful ROE decline to about 9.5% signals lower efficiency in converting equity into profits. Persistently falling ROE can reduce shareholder returns and indicate pricing, margin, or capital allocation strain that may limit long-term value creation.
Beijing Tong Ren Tang Chinese Medicine Co News
3613 FAQ
What was Beijing Tong Ren Tang Chinese Medicine Co Ltd’s price range in the past 12 months?
Beijing Tong Ren Tang Chinese Medicine Co Ltd lowest stock price was HK$6.21 and its highest was HK$9.72 in the past 12 months.
What is Beijing Tong Ren Tang Chinese Medicine Co Ltd’s market cap?
Beijing Tong Ren Tang Chinese Medicine Co Ltd’s market cap is HK$5.78B.
When is Beijing Tong Ren Tang Chinese Medicine Co Ltd’s upcoming earnings report date?
Beijing Tong Ren Tang Chinese Medicine Co Ltd’s upcoming earnings report date is Apr 01, 2027 which is in 235 days.
How were Beijing Tong Ren Tang Chinese Medicine Co Ltd’s earnings last quarter?
Currently, no data Available
Is Beijing Tong Ren Tang Chinese Medicine Co Ltd overvalued?
According to Wall Street analysts Beijing Tong Ren Tang Chinese Medicine Co Ltd’s price is currently Undervalued.
Does Beijing Tong Ren Tang Chinese Medicine Co Ltd pay dividends?
Beijing Tong Ren Tang Chinese Medicine Co Ltd pays a Notavailable dividend of HK$0.4 which represents an annual dividend yield of 5.36%. See more information on Beijing Tong Ren Tang Chinese Medicine Co Ltd dividends here
What is Beijing Tong Ren Tang Chinese Medicine Co Ltd’s EPS estimate?
Beijing Tong Ren Tang Chinese Medicine Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Beijing Tong Ren Tang Chinese Medicine Co Ltd have?
Beijing Tong Ren Tang Chinese Medicine Co Ltd has 837,100,000 shares outstanding.
What happened to Beijing Tong Ren Tang Chinese Medicine Co Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Beijing Tong Ren Tang Chinese Medicine Co Ltd?
Currently, no hedge funds are holding shares in HK:3613
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Beijing Tong Ren Tang Chinese Medicine Co Ltd
Beijing Tong Ren Tang Chinese Medicine Company Limited, encompassing its various affiliates, specializes in the production, distribution, and direct sale of traditional Chinese medicine and wellness items, catering to both corporate distributors and individual consumers. Its operations are geographically segmented across Hong Kong, Mainland China, and international markets. Additionally, the company provides traditional Chinese medical consultations and therapeutic services. The firm maintains a network of 23 retail stores throughout Hong Kong, complemented by 46 international outlets located across Asia, Oceania, North America, and Europe. All its offerings are sold under the well-recognized Tong Ren Tang brand. Established in 1669, the company's main office is situated in Wan Chai, Hong Kong.
3613 Stock 12 Month Forecast
Average Price Target
HK$10.50
▲(57.19% Upside)
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Tong Ren Tang Technologies Co
―
Modern Chinese Medicine Group Co. Ltd.
―
Gushengtang Holdings Limited
―
Shandong Xinhua Pharmaceutical Company Limited Class H
―